| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Research and development | $5.05B-59.7% | $12.54B-17.4% | $15.17B+122309.6% | $12.4M-99.9% | $8.79B+145640.8% | $6.0M |
| General and administrative | $3.96B-25.8% | $5.34B-10.8% | $5.99B+104164.6% | $5.7M-99.9% | $5.43B+97402.7% | $5.6M |
| Total operating expenses | $9.02B-49.6% | $17.88B-3.7% | $18.56B+47696.7% | $38.8M-99.7% | $14.22B+122494.8% | $11.6M |
| Loss from operations | -$9.02B+49.6% | -$17.88B+3.7% | -$18.56B-47696.7% | -$38.8M+99.7% | -$14.22B-148251.8% | -$9.6M |
| Interest income, net | $134.0M-75.0% | $537.0M-16.1% | $640.0M | — | — | — |
| Foreign exchange gain (loss) | $54.0M+133.1% | -$163.0M-150.8% | -$65.0M-361011.1% | -$18K+99.8% | -$9.0M | — |
| Total other income, net | $188.0M-49.7% | $374.0M-35.0% | $575.0M+7187600.0% | -$8K-100.0% | $36.0M+58164.5% | -$62K |
| Net loss | -$8.83B+49.5% | -$17.50B+2.7% | -$17.98B-46206.4% | -$38.8M+99.7% | -$14.19B-146925.3% | -$9.6M |
| Net loss per common share, basic | -$780.00+54.7% | -$1720.00+8.0% | -$1870.00+60.8% | -$4770.00-2981150.0% | -$0.16 | — |
| Net loss per common share, diluted | -$780.00+54.7% | -$1720.00+8.0% | -$1870.00+60.8% | -$4770.00 | — | — |
| Weighted average number of common shares outstanding, basic | 11.3M+11.0% | 10.2M+5.4% | 9.7M+18.5% | 8.1M+10.6% | 7.4M | — |
| Weighted average number of common shares outstanding, diluted | 11.3M+11.0% | 10.2M+5.4% | 9.7M+18.5% | 8.1M | — | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.